Biomerica, Inc. · NASDAQ:BMRA
Biomerica — Investor Presentation (July 2025)
30 slides from Biomerica's investor presentation, July 2025
Slide 1: Investor Presentation July 2025
Investor Presentation July 2025 Copyright © 2025 Biomerica. All Rights Reserved
Slide 2: Forward-Looking Statement
Forward-Looking Statement The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this presentation (as well as information included in oral statements or other written statements made or to be made by Biomerica) c
Slide 3: Who We Are
Who We Are Depth of Scientific Leadership Global Biomedical Company US Members of the Rome Develops, patents, Our customers Foundation Clinical studies lead manufactures & markets in USA by principal investigators who advanced diagnostics for set GI “treatment guidelines” use in Clinical lab, Point-
Slide 4: Leadership, Board & Depth in Science
Leadership, Board & Depth in Science Management Scientific Advisory Board inFoods® Principal Investigators ZACK IRANI-COHEN Principal Investigators or • Chief Executive Officer & Chairman Collaborators for: • Previous CEO & Chairman of Lancer DOUGLAS DROSSMAN, MD WILLIAM CHEY, MD, AGAF, Orthodontics
Slide 5: Transforming Diagnostics into Personalized Therapies
Transforming Diagnostics into Personalized Therapies Leveraging diagnostic expertise to transition into diagnostic-guided therapeutics Specialty diagnostics enabling early Disruptive patented technology disease detection and monitoring platform enabling diagnostic therapies Two FDA, CE, CFDA registe
Slide 6: inFoods – Diagnostic Guided Therapy (DGT) Personalize Medicine for IBS Patients
inFoods® – Diagnostic Guided Therapy (DGT) Personalize Medicine for IBS Patients Example of Patient-Specific Results Food Result Blueberry + POSITIVE Chicken NEGATIVE Cabbage NEGATIVE FDA-regulated diagnostic to be used as therapy Egg + POSITIVE Garlic NEGATIVE Measures immunoreactivity for a panel
Slide 7: Irritable Bowel Syndrome (IBS) is a Massive & Underserved Market
Irritable Bowel Syndrome (IBS) IBS is the #1 most common diagnosis made by IBS is the #7 most common diagnosis made by is a Massive & gastroenterologists1 all physicians1 Underserved Market IBS sufferers have 74% IBS patients visit doctors 3x more direct healthcare more than non-IBS patients costs v
Slide 8: IBS Market Opportunity $30B+
M IBS Market Opportunity Significant Today and Growing D C 40 Million IBS Patients in the US $30B+ 1/3 IBS-C (Constipation) 1/3 IBS-D (Diarrhea) 1/3 IBS-M (Mixed: Alternates C+D) U.S. TAM1 IBS = recurrent abdominal pain & change in bowel habits ~16 M I L L I O N US IBS Patients: seeking consistent p
Slide 9: Clinical Study: Largest Study of Its Kind
Clinical Study: Largest Study of Its Kind Copyright © 2025 Biomerica. All Rights Reserved 9
Slide 10: inFoods IBS: Robust Study Design Validates inFoods
inFoods® IBS: Robust Study Design Validates inFoods Randomized Double Blinded Placebo controlled Food consumption survey Patient is inFoods positive to: Blueberries & Almonds Treatment Arm Placebo Arm 1:1 Eliminates Eliminates Blueberries & Almonds Raspberries & Walnuts (if negative and same consump
Slide 11: inFoods Delivers Global Therapy Endpoints
inFoods Delivers Global Therapy Endpoints Significant Symptom Relief vs Placebo Treatment Arm Vs. Placebo Arm Significant symptom relief seen across multiple IBS subtypes SGA P-value of 0.007 for improvement in the Subject’s Global Assessment of Relief (SGA) endpoint for all patient subtypes as a gr
Slide 12: inFoods Delivers Pain & Bloating Endpoints
inFoods Delivers Pain & Bloating Endpoints Significant Symptom Relief vs Placebo Treatment Arm Vs. Placebo Arm Significant symptom relief seen across multiple IBS subtypes API P-value of 0.012 for improvement in the Abdominal Pain Intensity (API) endpoint for IBS- Mixed & IBS-Constipation patients a
Slide 13: FDA-Approved IBS Drugs Are High-Cost & Low-Relief with Safety Limitations
FDA-Approved IBS Drugs Are High-Cost & Low-Relief with Safety Limitations Efficacy: FDA Treatment Placebo Monthly Annualized Indication Drug Treatment Limitations Approval Response Response Cost U.S. Sale minus Placebo • Diarrhea side Linzess 2012 20% - 34% 6% - 27% 7% - 14% $467 $1,963M effect (20%
Slide 14: First Therapeutic Approach for IBS-M Patients
First Therapeutic Approach for IBS-M Patients P=0.02 P=0.01 Copyright © 2025 Biomerica. All Rights Reserved
Slide 15: Significant Reduction in Abdominal Pain Intensity & Bloating
Significant Reduction in Abdominal Pain Intensity & Bloating Copyright © 2025 Biomerica. All Rights Reserved 15
Slide 16: Gastroenterology: Primary Endpoint Met
Published in: Primary Endpoint Met June 2025 issue of Gastroenterology Gastroenterology is the leading GI publication Copyright © 2025 Biomerica. All Rights Reserved 16
Slide 17: inFoods Commercialization Strategy
inFoods® Commercialization Strategy Multiple Avenues to Drive Adoption Reimbursement Awareness Inclusion in Guidelines Broad Physician Interest and Enhanced Coverage Inclusion in the IBS treatment Help GI physicians monetize Capitalize on strong physician guidelines will accelerate their largest pat
Slide 18: Launch of inFoods IBS as LDT with Gastro Health
Launch of inFoods IBS as LDT with Gastro Health Relationship with Gastro Health (GH): A leading gastroenterology group with over 390 employed GI physicians. A leader in advanced innovation and technology in GI patient care. Operates over 100 patient care centers in Alabama, Florida, Maryland, Massac
Slide 19: inFoods IBS: Whole Blood & Self Collection
inFoods IBS: Whole Blood & Self Collection inFoods® IBS: Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology Finger stick (capillary) patient whole blood samples simplify sample collection and facilitate wider access to the test. Doctor’s Office Collection Any trained me
Slide 20: inFoods IBS: Broad Benefits to Patients, Physicians, and Healthcare Insurers
inFoods® IBS: Broad Benefits to Patients, Physicians, and Healthcare Insurers Targets 100% of the IBS Market (IBS-M, IBS-C, IBS-D)1 Patient Benefits Physician Benefits Payer/insurer Benefits inFoods® targets underlying inFoods® recurring revenue inFoods® insurer savings causes without causing potent
Slide 21: Insurance Reimbursement: PLA Code
Insurance Reimbursement: PLA Code inFoods® IBS receives Proprietary Laboratory Analysis (PLA) Code PLA Code issuance marks a significant step toward attaining health insurance reimbursement and expanded patient access for inFoods IBS. American Medical Association CPT editorial panel has issued a Pro
Slide 22: Platform Technology: inFoods Development Pipeline
Platform inFoods® Technology: Development Pipeline Product End CLIA LDT Pivotal Trial & IP & Data FDA Sub Q Dev. R&D Point Trial Launch FDA Approval 18 Foods Irritable Bowel Syndrome (IBS) Functional Gastrointestinal 37 Foods Functional Dyspepsia Disorders 19 Foods GERD disease Gastrointestinal 58 F
Slide 23: Specialty Diagnostics
Specialty Diagnostics Copyright © 2025 Biomerica. All Rights Reserved 23
Slide 24: 2025 Growth Opportunity - H. pylori
2025 Growth Opportunity - H. pylori Status: Biomerica received FDA 510K clearance Detects H. pylori Antigen Gastric Cancer: Gastric cancer is the 3rd most common cause of cancer related death in the world. Over 80% of gastric cancers are attributed to H. pylori infection. In 2017, the World Health O
Slide 25: Colorectal Disease Test: EZ Detect
Colorectal Disease Test: EZ Detect EZ Detect is a 2-minute, at-home test for Quick & Simple: the determination of fecal occult blood, an early warning sign of colorectal cancer (CRC) and other colorectal diseases. No Stool Handling 1 2 3 Interpretation Negative Positive Positive Any color in the tes
Slide 26: Low Cost Compared to Other Screening Tests & Same Consequence
Low Cost Compared to Other Screening Tests & Same Consequence Value EZ DetectTM Cologuard®1 FIT1 List Price $18 $649 $22 Accuracy 93.2% 86.6% 94.7% Specificity 99.2% 86.6% 94.9% (vs. all negative findings on Colo colonoscopy/sigmoidoscopy) (124 / 125) (7936 / 9167) (8695 / 9167) Sensitivity 72.9% 92
Slide 27: Prostate (PSA) Screening Test
Prostate (PSA) Screening Test The Fortel® Prostate (PSA) Screening test is a simple at-home visual test to detect elevated levels of Prostate Specific Antigen (PSA) using a finger prick blood sample Laboratory accuracy in the comfort of your home Results in 10 minutes Prostate (PSA) screening made e
Slide 28: Laboratory Accuracy
Laboratory Accuracy Reference Method Clinical Study #1 Performance vs. Reference Method Positive Negative Total Fortel® (Immulite 2000/ Abbott Axsym Total Prostate Positive 80 4 84 PSA /Roche E170 tests) (PSA) Screening Negative 0 77 77 Sensitivity: 100% Test Total 80 81 161 Specificity: 95% • Clini
Slide 29: Insurance reimbursement & distribution
Insurance reimbursement & distribution New multi-year exclusive distribution agreement with leading UAE healthcare company recently signed Dubai Government Grants Insurance Reimbursement for EZ Detect In discussions with other governments for Insurance Reimbursement in UAE and other MENA countries F
Slide 30: Leveraging Our Unique Technology
Disruptive Patented Platform Technology redefining the GI Market Addressing the large need for IBS patients and then targeting multiple other diseases inFoods Model is Unique Leveraging Benefits Patient / Physician / Insurer Our Unique Broad IP Protection Robust patent portfolio (35 issued patents;